

Zydus acquires the gastro therapy 'Actibile' from Albert David Limited *Strengthens its presence in the gastroenterology segment*

Ahmedabad, March 28, 2016

The Zydus Group, an innovation-led global healthcare provider announced that Zydus Healthcare Limited, a wholly owned subsidiary of Cadila Healthcare Limited has entered into a definitive agreement to acquire 'Actibile' from Albert David Limited (ADL). The brand falls in the gastroenterology segment and is used for dissolving gall bladder stones. The deal will be financed through internal accruals.

Speaking on the development, Chairman and Managing Director of the group, Mr. Pankaj R. Patel said, "The gastrointestinal segment has been one of our core focus segments and we have been working with the medical fraternity to serve patient needs better. I believe that this acquisition will strengthen our portfolio of brands and leverage our equity in this key segment."

About Zydus Cadila

Headquartered in Ahmedabad, India, Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19000 people worldwide. The group has a strong research pipeline of NCEs, biologics and vaccines and has over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. As a leading healthcare provider, it aims to become a global research based pharmaceutical company by 2020.

About ADL

Albert David Limited, listed on the Bombay Stock Exchange Limited (524075), is the pharmaceutical venture of the INR 2000 crores Kothari Group, a Kolkata head-quartered industrial group. Kothari Group has a significant presence in Pharmaceuticals, Machine Tools, Tea Plantations and Healthcare. Albert David Limited is involved in manufacturing and marketing of branded formulations in India and abroad and also has operations in medical disposables. Additional information is available on ADL's website at www.albertdavidindia.com